Nova Eye Medical (ASX:EYE) ROCE %: -33.53% (As of Dec. 2025)

What is Nova Eye Medical ROCE %?

Nova Eye Medical ASX:EYE +2.44% 55 ROCE % is -33.53% as of Dec. 2025. GuruFocus rates ASX:EYE with a GF Score™ of 55/100 and a GF Value™ of A$0.18 (Possible Value Trap). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nova Eye Medical's annualized ROCE % for the quarter that ended in Dec. 2025 was -33.53%.

Nova Eye Medical (ASX:EYE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Nova Eye Medical ROCE % Related Terms

Nova Eye Medical ROCE % Historical Data

* Premium members only.

The historical data trend for Nova Eye Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nova Eye Medical ROCE % Chart

Nova Eye Medical Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

ROCE %

Get a 7-Day Free Trial

-7.51

-27.68

-42.20

-37.15

-49.38

Nova Eye Medical Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
ROCE %	Get a 7-Day Free Trial															-53.89	-32.12	-48.20	-56.74	-33.53

55GF Score

Nova Eye Medical Ltd ASX:EYE

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Nova Eye Medical ROCE % Calculation

Nova Eye Medical's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2025 )		(A: Jun. 2024 )		(A: Jun. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2025 )		(A: Jun. 2024 )		(A: Jun. 2025 )
	=	-11.246	/	( ( (29.882 - 5.683)	+	(26.504 - 5.154) )	/ 2 )
	=	-11.246	/	( (24.199	+	21.35)	/ 2 )
	=	-11.246	/	22.7745
	=	-49.38 %

Nova Eye Medical's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2025 )		(Q: Jun. 2025 )		(Q: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2025 )		(Q: Jun. 2025 )		(Q: Dec. 2025 )
	=	-6.592	/	( ( (26.504 - 5.154)	+	(23.673 - 5.703) )	/ 2 )
	=	-6.592	/	( ( 21.35	+	17.97 )	/ 2 )
	=	-6.592	/	19.66
	=	-33.53 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -33.53% mean?

Nova Eye Medical (ASX:EYE) has a ROCE % of -33.53% as of Dec. 2025.

Is Nova Eye Medical's ROCE % too high?

Nova Eye Medical's current ROCE % is -33.53%. Overall, Nova Eye Medical has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Nova Eye Medical's ROCE % compare to ABT and SYK?

Nova Eye Medical's ROCE % of -33.53% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nova Eye Medical's current ROCE % is -33.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Nova Eye Medical stock overvalued right now?

Based on GuruFocus' analysis, Nova Eye Medical (ASX:EYE) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.18, compared to a current price of A$0.11 — trading 41.7% below its estimated fair value. The current ROCE % is -33.53%. Nova Eye Medical's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Nova Eye Medical (ASX:EYE), the current ROCE % is -33.53% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nova Eye Medical (ASX:EYE) Overvalued in 2026?

Based on GuruFocus' analysis, Nova Eye Medical stock appears to be undervalued. The current stock price of A$0.11 is trading 41.7% below its estimated GF Value™ of A$0.18. GuruFocus considers Nova Eye Medical to be Possible Value Trap.

Key valuation signals for ASX:EYE:

ROCE %: -33.53%
GF Value™: A$0.18 vs. price of A$0.11 (41.7% below fair value)
GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the ASX:EYE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nova Eye Medical Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies ASX:CSX ASX:MX1 ASX:CVB ASX:CBL ASX:AT1 ASX:CQT ASX:HMD ASX:OSL ASX:IPD ASX:MEM ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Address 107 Rundle Street, Kent Town, Adelaide, SA, AUS, 5067

Website https://www.nova-eye.com

Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.

55GF Score

Get the complete analysis for ASX:EYE

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11

Price

A$0.18

GF Value

View ASX:EYE Analysis

See ROCE % data for all stocks →